UNSPSC 51172304: Edetate disodium

This classification denotes a chelating agent with the molecular formula C10H12N2O8.2H+.2Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7FLD91C86K, chemically known as 3,6-diazaoctanedioic acid, 3,6-bis(carboxymethyl)- but generally known as disodium edetate, which bears US NIH Compound Identifier 6049. European Medicines Agency schedules Disodium edetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11914MIG.

As of Q4 2014, EDETATE DISODIUM remains the US FDA Preferred Term for this commodity. Edetate disodium bears US NLM identifiers UMLS ID C0012695 and NCI Concept Code C61741. SMILES: OC(=O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.

UNSPSC 51172304 Edetate disodium is a Commodity code that in recent state and local procurement activity covers laboratory drug testing and specimen collection services, pharmaceutical supply agreements, and related clinical chemistry consumables used in criminal justice, healthcare benefit, and multistate cooperative purchasing contexts. The code appears in solicitations from county corrections departments, state health and human services agencies, and multistate cooperative purchasing alliances procuring immunoassay screening supplies, confirmation testing reagents, and ancillary materials to support drug testing operations and pharmacy benefit programs. The issuing bodies include county community supervision departments, state health commissions, and regional cooperative purchasing organizations serving multiple jurisdictions across state and local government.

Recent activity spans Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with a response deadline of July 23, 2026, seeking immunoassay screening and LC/MS/MS or GC/MS confirmation testing capacity with an estimated contract value of $600,000 over two years with optional renewals; the contract requires lab certification from SAMHSA, TX DPS, or CAP and encompasses approximately 25,031 annual tests across five-panel and six-panel screening protocols with oral fluid and hair testing alternatives. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor information on direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives, signaling future procurement interest in pharmaceutical supply chain optimization outside traditional PBM and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers with pricing effective July 1, 2026 and a two-year initial term with optional extensions through June 30, 2028.